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Abstract
The cellular form of the prion protein (PrPc) is necessary for the development of prion diseases and
is a highly conserved protein that may play a role in neuroprotection. PrPc is found in both blood and
cerebrospinal fluid and is likely produced by both peripheral tissues and the central nervous system
(CNS). Exchange of PrPc between the brain and peripheral tissues could have important
pathophysiologic and therapeutic implications, but it is unknown whether PrPc can cross the blood–
brain barrier (BBB). Here, we found that radioactively labeled PrPc crossed the BBB in both the
brain-to-blood and blood-to-brain directions. PrPc was enzymatically stable in blood and in brain,
was cleared by liver and kidney, and was sequestered by spleen and the cervical lymph nodes.
Circulating PrPc entered all regions of the CNS, but uptake by the lumbar and cervical spinal cord,
hypothalamus, thalamus, and striatum was particularly high. These results show that PrPc has
bidirectional, saturable transport across the BBB and selectively targets some CNS regions. Such
transport may play a role in PrPc function and prion replication.
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Introduction
Cellular prion protein (PrPc) is perhaps best known as a source for the misfolded protein
PrPsc (Prusiner, 1997) and as a prerequisite for the development of prion diseases (Mallucci et
al., 2000). However, PrPc itself likely has important biological functions. It is found circulating
in blood (Volkel et al., 2001) and is found in even higher levels in the cerebrospinal fluid (CSF)
(Picard-Hagen et al., 2006). After ischemic events, PrPc levels increase in blood (Mitsios et
al., 2007) and in neurons and brain endothelial cells in the peri-infarct region (Mitsios et al.,
2007; Weise et al., 2004). These increases may reflect cytoprotective and neuroprotective roles
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for PrPc as recently reviewed (Roucou & LeBlanc, 2005). PrPc null mice have larger infarct
volumes after ischemic events (Weise et al., 2006; Nasu-Nishimura et al., 2008) and more
neuronal apoptosis after viral infections (Nasu-Nishimura et al., 2008) than wild type mice. In
comparison, mice that overexpress PrPc have smaller infarcts and better neurological outcomes
than wild type mice after ischemic events (Shyu et al., 2005). These protective events are likely
mediated by PrPc through activation of anti-apoptotic (Spudich et al., 2005) and anti-oxidant
pathways (White et al., 1999).
Sources of circulating PrPc likely include platelets (Robertson et al., 2006), endothelial cells
(Simak et al., 2002), and lymphocytes (Politopoulou et al., 2000). Among lymphocytes, CD3
and CD8 lymphocytes have especially high levels which increase with aging (Politopoulou et
al., 2000) All these cells have membrane bound PrPc that apparently can be released into the
circulation. Platelet activation (Robertson et al., 2006) or endothelial apoptosis (Simak et al.,
2002), for example, results in release of PrPc from those cells.
Thus, PrPc occurs in both blood and in CSF with levels that are likely responsive to disease
states. This raises the question of whether PrPc can cross the blood–brain barrier (BBB). Such
passage could link the two pools of PrPc and the events that control their levels. Here, we
examined the ability of PrPc to cross the BBB in both the blood-to-brain and the brain-to-blood
directions.
Materials and methods
Production and purification of PrPc
Murine prpc gene (residues 23–230) was PCR-amplified from mouse blood sample using
standard molecular biology techniques. The amplicon was inserted in a pET303/CT His vector
(Invitrogen®) and propagated in DH10B-T1R E. coli cells (Invitrogen®). The plasmid was
purified and then transformed into BL21-Star E. coli cells (Invitrogen®). For expression,
freshly transformed cells were grown in 5 ml of TB medium supplemented with kanamicin
(100 μg/ml) at 37 °C for 6 h. The starter culture was then diluted into 50 ml of the same medium
and grown for another 6 h. This culture was finally diluted in 750 ml of the same medium and
grown until it reached 0.7 OD. 1 mM IPTG was then added and the cells were induced for an
additional 5 h. The cells were harvested by centrifugation and kept at −80 °C until purification.
For purification, cell pellets were thawed and resuspended in buffer A (50 mM Tris–HCl pH
8.0, 1 mM EDTA and 100 mM NaCl). Cells were lysed by adding 0.5 mg/ml Lysozyme and
subsequently sonicated. The released inclusion bodies were pelleted by centrifugation at 22,000
×g and then washed twice with buffer A supplemented with 0.05% (v/v) Triton X-100. The
inclusion bodies containing PrPc were solubilized for 2 h with buffer B (10 mM Tris–HCl, 100
mM Na2HPO4 pH 8.0, 100 mM NaCl, 10 mM B-Mercaptoethanol, 6 M GdnCl) and then
purified by using standard IMAC procedure. Briefly, the sample was bound to Ni Sepharose
6 Fast Flow resin (GE Healthcare®) in batch-mode for 1 h at RT and then washed with buffer
B. PrPc was on-column refolded for 6 h and eluted with 500 mM Imidazole. The main peak
was collected and quickly filtered to remove aggregates. The sample was buffer-exchanged by
using Zeba-desalting columns (Pierce®), further concentrated to ∼0.5 mg/ml and flash-frozen
at −80 °C. Protein inhibitors (Complete Protease Inhibitor Cocktail from Roche®) were used
throughout the purification to minimize degradation. The protein was confirmed to be
monomeric and folded by SDS-PAGE, Western blotting and Circular Dichroism.
Radioactive Labeling of PrPc was radioactively labeled by the iodobead method. In brief, 100
μl of 0.1% SB3-14 (Sigma Chemical Co., St. Louis, MO) in 0.25 M sodium phosphate buffer
solution was added to a polypropylene tube containing 2 mCi 131 I. A washed iodiobead
(Pierce, Inc., Rockford, IL) was added to the mixture and left to incubate for 5 min at room
temperature. PrPc (10 μg) was added and allowed to incubate for 5 min. This mixture was
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added to a G-10 Sephadex column previously washed and then eluted with 0.1%SB3-14 in
0.25 M sodium phosphate buffer, pH 7.4. The I-PrPc eluted in fraction 8 (RF 1.6) with 83%
precipitation in acidified brine (30% trichloroacetic acid in a saturated solution of NaCl).
Distribution uptake by brain and peripheral tissues
Male CD-1 mice from our in-house colony (VA-St. Louis) were anesthetized with 40%
urethane. All animal studies were done in accordance with international standards and under
protocols approved by our local animal use committee. The right jugular vein and the left
carotid artery were exposed. At t = 0, 0.2 ml of lactated Ringer's solution containing 1% bovine
serum albumin (LR-BSA) and 250,000 cpm I-PrPc was injected into the jugular vein. At various
times after the iv injection, blood was collected from the carotid artery and the mouse
immediately decapitated and kidney, liver, spleen, and cervical lymph nodes were collected
and weighed. The arterial blood was centrifuged and arterial serum collected. The levels of
radioactivity were determined in the serum and tissues. Results were expressed as the percent
of the iv injected dose of I-PrPc in 1 ml of serum (%Inj/ml) or as tissue/serum ratios (μl/g).
Whole body distribution and clearance from blood was determined by plotting the log of %
Inj/ml vs time. The antilog of the inverse of this intercept was multiplied by 100 to yield Vd
(ml). A two phase exponential decay curve was applied to calculate the fast and slow clearance
rates from blood.
The unidirectional influx rate (Ki, in units of μl/g-min) from blood-to-brain was calculated by
multiple-time regression analysis (Blasberg et al., 1983; Patlak et al., 1983). In brief, the brain/
serum ratio was plotted against exposure time, where exposure time (Expt) was calculated as:
The slope for the linear portion of the relation between brain/serum ratios and Expt measures
Ki. The intercept for this line (Vi, in units of μl/g) measures the initial (t = 0) distribution space
in brain and reflects the vascular space of the brain plus any reversible binding to the luminal
surface of brain endothelial cells. Uptake rates for the peripheral tissues were measured by
plotting their tissue/serum ratios against Expt.
Regional uptake within the CNS
Male CD-1 mice from our in-house colony were anesthetized with 40% urethane and given an
injection into the right jugular vein of LR-BSA containing I-PrPc with or without 10 μg/mouse
of unlabeled PrPc (n = 6/group). Twenty minutes later, arterial serum, olfactory bulb, whole
brain, and spinal cord were collected from each mouse. The whole brain was dissected into 10
regions (frontal cortex, parietal cortex, occipital cortex, striatum, hippocampus, hypothalamus,
thalamus, pons-medulla, cerebellum, and midbrain) after the method of Glowinski & Iversen
(1966) and the spinal cord divided into its cervical, thoracic, and lumbar regions. Brain and
spinal cord regions were weighed, the level of radioactivity determined, and the results
expressed as the brain/serum ratios in units of μl/g. The values for whole brain were calculated
by adding together the levels of radioactivity or weights for the 10 brain regions with exclusion
of data for olfactory bulb and spinal cord regions.
In vivo stability in brain and blood
Arterial serum obtained 5–60 min after the iv injection of I-PrPc was allowed to clot and 50
μl of the resulting serum added to 250 μl of LR-BSA and then to 250 μl of acidified brine
containing 30% trichloroacetic acid. The mixture was vigorously mixed and centrifuged at
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5400 ×g for 15 min at 4 °C. The resultant supernatant and precipitate were separated and
counted and the results expressed as the percent of total counts that were precipitated.
Brains obtained 5–60 min after the iv injection of I-PrPc were homogenized with a glass
homogenizer in 3 ml of LR-BSA and then centrifuged at 5400 ×g for 10 min at 4 °C. An aliquot
of 1.5 ml of the supernatant was added to 1.5 ml of acidified brine containing 30% trichoroacetic
acid, the mixture vigorously mixed, and then centrifuged at 5400 ×g for 10 min at 4 °C. The
supernatant and precipitate were separated and counted and the results expressed as the percent
of total counts that precipitated.
To correct for any degradation that might have occurred during the processing for acid
precipitation, we added I-PrPc to non-radioactive arterial whole blood or to whole brain. These
samples were then processed as above and the percent of total counts that were precipitated
determined. The mean of 4 processing controls was 72% for serum and 63% for brain. The
values for the biological samples were divided by the value of the processing control and
multiplied by 100 to give the reported results.
Capillary depletion
Capillary depletion as modified for use in the mouse (Triguero et al., 1990; Gutierrez et al.,
1993) was used to determine the degree to which PrPc was sequestered and retained by the
vascular bed of the brain. Mice were anesthetized with urethane and given an injection into the
jugular vein of 0.2 ml saline containing 750,000 cpm of PrPc labeled with 131I and albumin
labeled with 125I. Twenty minutes later, arterial blood was obtained from the abdominal aorta.
In other mice, the thorax was opened and the descending thoracic aorta clamped after obtaining
the blood, both jugular veins severed, and the blood washed out of the brain by injecting 20
ml of lactated Ringer's solution into the left ventricle of the heart in 60 s. The brain was removed
and emulsified in a glass homogenizer (8–10 strokes) at 4 °C in a 9-fold volume of physiological
buffer (10 mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM MgSO4, 1 mM
NaH2PO4, and 10 mM D-glucose adjusted to pH 7.4). Dextran solution was added to the
homogenate to a final concentration of 26%. An aliquot was centrifuged at 5400 ×g for 15 min
at 4 °C in a swinging bucket rotor. The pellet containing the brain microvessels and the
supernatant containing the brain parenchyma were carefully separated. Results were expressed
as capillary/serum and parenchyma/serum ratios. Values for albumin were subtracted from
those for PrPc to yield values corrected for residual vascular contamination.
Brain-to-blood efflux
The intracerebroventricular (icv) injection method as previously described was used to quantify
efflux of I-PrPc (Banks & Kastin, 1989; Banks et al., 1997a; Banks & Broadwell, 1994; Cashion
et al., 1996). Two month old male CD-1 mice from our in-house colonies were kept on a 12/12
h light/dark cycle with food and water freely available. They were anesthetized on day of study
with 0.15 ml of 40% urethane. The scalp was removed and a hole made into the lateral ventricle,
1.0 mm lateral and 1.0 mm posterior to the bregma, with a 26 ga needle with a tubing guard
which kept the depth of the holes constant (3.0–3.5 mm). Mice received 1.0 μl icv injections
containing 5(103) cpm I-PrPc in LR-BSA. Mice were decapitated at 2, 5, 10, and 20 min after
injection. The whole brain was removed, the pituitary and pineal glands were discarded, and
the level of residual radioactivity in the whole brain was determined from the counts after 3
min in a gamma counter. The level of radioactivity in whole brain at t = 0 was determined in
mice overdosed with anesthetic as previously described (Banks & Kastin, 1989). The cpm
remaining in the brain was divided by the cpm injected and multiplied by 100 to yield the
percent of the injected dose remaining in brain (%Inj/brain). The log of %Inj/brain was
regressed against time. A significant correlation between log (%Inj/brain) and time indicated
a measurable efflux from brain-to-blood of the injected substance, with the slope of this relation
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measuring the rate of efflux. In other mice, only the 10 min value was assessed with some
injections containing 1 μg/mouse of non-radioactive PrPc. These data were not transformed by
log but the arithmetic means compared by t-test.
Statistics
Linear regression analysis including calculation of slopes with error terms was conducted by
the least squares method with the Prism 5.0 statistical package (GraphPad, Inc., San Diego,
CA). Means are reported with their error terms and number per statistical cell (n). Means were
compared by t-test.
Results
Fig. 1 shows the clearance of I-PrPc from blood after its iv injection. A two phase decay model
was applied to the results which yielded a fast half-life of 0.65 min and a slow half-life of 12
min (n = 28, r = 0.911). As shown in Table 1, no degradation was detected in blood for 60 min.
Fig. 2 shows the uptake of I-PrPc by brain. The inset shows that a steady state of 21.6 μl/g was
approached. Entry into brain was linear for the first 30 min of exposure time after iv injection
with a Ki of 0.305 ± 0.020 μl/g-min (n = 17, r = 0.969, p <0.0001). Table 1 shows degradation
in brain beyond 20 min of clock time (about 30 min exposure time) but with significant amounts
of intact I-PrPc still in brain at 60 min.
Fig. 3 shows that the majority of I-PrPc taken up by brain was able to traverse the width of the
capillary wall to enter the parenchymal space of the brain. Only a small percent was retained
by the capillaries. Inclusion of washout did not affect results, demonstrating that little or no I-
PrPc was reversibly adhering to the luminal surface of the capillary bed.
I-PrPc was also taken up by the peripheral tissues of spleen, liver, kidney and cervical lymph
nodes (Table 2). Uptake was not saturated by the inclusion of 10 μg/mouse in the iv injection
for any of the peripheral tissues nor was clearance from blood affected. However, there was a
statistically significant decrease in the Ki for brain: F(1,8) = 7.97, p <0.05. This demonstrates
that transport of PrPc across the BBB involves a saturable transport system.
Fig. 4 shows values for brain and spinal cord regions. Statistical comparison of the whole brain
value to brain regions and olfactory bulb (spinal cord regions excluded) showed a statistically
significant variation: F(22,62) = 18.3, p <0.001. The hypothalamus, thalamus, and striatum
showed statistically (p <0.01) greater uptake in comparison to whole brain. The highest uptake,
however, was into the lumbar region of the spinal cord. Inhibition of uptake by unlabeled
PrPc (Table 3; p <0.05) was found for whole brain, olfactory bulb, 4 of the 10 brain regions
(occipital cortex, thalamus, striatum, and midbrain) and two of the spinal cord regions (cervical
and lumbar).
I-PrPc was rapidly cleared from the brain after its injection into the lateral ventricle (Fig. 5),
with a half-time clearance from brain of 15.7 min (n = 10, r = 0–832, p <0.005). The inset of
Fig. 4 shows that inclusion of 1 μg/mouse of unlabeled PrPc significantly inhibited the efflux
of I-PrPc [n = 7/group, t(13) = 2.61, p <0.05].
Discussion
Here, we examined the ability of PrPsc to cross the BBB. Whereas there has been interest in
how PrPsc crosses the BBB, no work to date has been done on PrPc. It is clear, however, that
PrPc is present in both the blood and in the CNS and that both brain and blood levels of PrPc
are responsive to CNS injury. These findings raise the question of whether PrPc can cross the
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BBB. Furthermore, the results suggesting a neuroprotective role for PrPc also raise the question
of whether it can cross the BBB and potentially be used therapeutically.
Here we found that PrPc crossed the BBB bidirectionally; that is, in both the brain-to-blood
(efflux) and blood-to-brain (influx) directions. Transport of radioactively labeled PrPc in either
direction was shown to be saturable with unlabeled PrPc. Such bidirectional transport occurs
for other molecules whose CNS levels are important to function and are tightly regulated, such
as potassium and glucose (Daniel et al., 1978; Bradbury et al., 1972). Bidirectional transport
has also been found for many peptides with therapeutic or pathological potential, such as
pituitary adenylate cyclase activating polypeptide (Banks et al., 1993) and beta amyloid protein
(Deane et al., 2004a; LaRue et al., 2004). Which direction dominates can vary as a function of
substance (Deane et al., 2004b) or physiologic state (Bradbury et al., 1972).
The unidirectional influx rate of 0.305 μl/g-min is about 300 times slower than found for large
neutral amino acids (Segal et al., 1990) and about 100 times faster than typically found for
albumin (Banks et al., 1988). This rate is similar to the rates found for CNS active proteins
such as leptin, insulin, and cytokines (Banks et al., 1996; Banks et al., 1997b; Banks et al.,
1991).
We used the icv injection method to determine the rate of brain-to-blood transport. This method
can also be used for direct brain injection (Banks et al., 1994), but when the icv injection route
is used, it assesses contributions by both the choroid plexus and capillary bed (Maness et al.,
1996; Maness et al., 1998). Use of the full time course as used here produces actual efflux
kinetics rather than values indexed to a reference molecule.
PrPc showed enzymatic stability in both blood and brain tissue. This suggests that blood-borne
PrPc could contribute significantly to brain levels of PrPc and that efflux from brain could also
contribute to blood levels. Similar mixing of CNS and peripheral pools of peptide also occurs
for amyloid beta protein (DeMattos et al., 2002), another protein that can result in CNS toxicity
because of misfolding (Soto et al., 2000). The pathophysiological implications of such mixing
are not well understood, nor is it clearly determined for either amyloid beta protein or for
PrPc whether efflux or influx dominate in determining levels in brain. Levels of PrPc in sheep
CSF (Picard-Hagen et al., 2006) and human blood (Volkel et al., 2001) are similar (9.6 ng/ml
and 6.2 ng/ml, respectively), suggesting that an equilibrium between the two exists. Here,
radioactively labeled PrPc had a significant residence time in blood, with about 10% of the
injected dose still present in 1 ml of blood 120 min after iv injection. Thus, any secreted
PrPc has a significant period in which to cross the BBB. This also indicates that PrPc has a
favorable pharmacokinetic profile if used as a therapeutic for neuroprotection.
Capillary depletion with washout showed that little or no PrPc adhered to the luminal surface
of the capillaries. Irreversible adherence or uptake by the capillaries is shown by high uptake
in the capillary fraction and reversible adherence is indicated by a lower value for the
parenchymal fraction in washout compared to non-washout animals. The Vi in Fig. 2 is about
11 μl/g which is comparable to the brain's vascular space and supports the conjecture that there
is little adherence to the luminal surface of brain endothelial cells. This lack of adherence is in
marked contrast to amyloid beta protein, especially the 40mer form (Maness et al., 1994;Martel
et al., 1996), which shows the majority of material associated with the capillary fraction.
PrPc was also taken up by peripheral tissues. Uptake of PrPc by liver and kidney was high,
indicating that both of these tissues are important for clearance. Spleen and cervical lymph
nodes also took up PrPc. These tissues also take up PrPsc, suggesting that both the native and
misfolded forms of the protein may be using similar mechanisms for uptake and distribution
in the body. No saturable component to PrPc uptake by kidney, liver, spleen, or cervical nodes
could be demonstrated with 10 μg/mouse of unlabeled material. These results suggest that
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PrPc is taken up by these tissues by a non-saturable mechanism, but it is theoretically possible
that a saturable system is present that requires higher doses for saturation. Based on the
pharmacokinetics shown in Fig. 1, the dose of 10 μg/mouse produces blood levels of about 1
μg/ml. Since this exceeds the endogenous blood level of PrPc in humans of 6.2 ng/ml (3134)
by over 100 fold, it is unlikely that PrPc by itself would ever saturate any such transporter.
These findings emphasize the importance of examining uptake, especially of the BBB, for
saturable components.
Brain uptake of PrPc was found to be saturable in two separate experiments shown in Table 2
and in Table 3. PrPc uptake was also widely distributed throughout the CNS. However, the
hypothalamus, thalamus, and striatum had high rates of uptake and are often the regions most
affected in prion disease (DeArmond et al., 1993). Although it is known that PrPsc can cross
the BBB (Banks et al., 2004), it is not known whether PrPsc uses the PrPc transporter to do so.
Most of the highest transport regions showed saturable inhibition, the one exception being the
hypothalamus. This high rate of entry with absence of saturation could be caused by a system
with a high transport capacity. The lumbar spinal cord showed the highest uptake rate of any
CNS region and we showed that it had a significant saturable component. Interestingly, the
spinal cord has been suggested as an important entry site for PrPsc (Kimberlin et al., 1987),
again suggesting that both forms of the protein may be using the same transporters for uptake,
clearance, or distribution.
The uptake of PrPc by a number of brain regions raises the possibility that it may be affecting
various aspects of brain function or even altering BBB function. Amyloid beta protein, for
example, has been shown to alter various aspects of BBB function, including monocyte
migration (Giri et al., 2000). Such actions would be consistent with the neuroprotective role
suggested for PrPc as discussed above.
In summary, PrPc is transported by a saturable mechanism both into and out of the CNS. Uptake
from blood occurs throughout the CNS and is particularly high for lumbar and cervical spinal
cord, hypothalamus, thalamus, striatum the olfactory bulb, and occipital cortex. Radioactively
labeled PrPc is stable in blood and brain, suggesting that PrPc produced in either the CNS or
peripheral tissue compartment could contribute to the levels in the other compartment. Overall,
these results show that PrPc can readily cross the BBB in both the brain-to-blood or blood-to-
brain directions.
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Fig. 1.
Clearance of radioactively labeled PrPc from blood after iv injection. Fast and slow components
to the half-time clearance were 0.65 and 12 min, respectively.
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Fig. 2.
Uptake by brain of PrPc after its iv injection. The inset shows that a steady state maximum
value of 21.6 μl/g was approached. The unidirectional influx rate (main panel) showed a Ki =
0.305 ± 0.02 μl/g-min.
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Fig. 3.
Capillary depletion with or without vascular washout. The majority of PrPc was in the
parenchymal space, demonstrating that PrPc was not sequestered by the capillary bed but
crossed the full thickness of the capillary wall. Washout produced no difference in parenchymal
values, showing that PrPc was not reversibly retained by the luminal surface of the capillary
bed.
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Fig. 4.
Regional uptake of PrPc by the CNS. *p <0.05 compares brain regions to whole brain values.
The cervical and lumbar thoracic regions also differed from whole brain values.
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Fig. 5.
Brain-to-blood efflux of PrPc after icv injection. Half-time clearance from brain was 15.7 min.
Inset shows that inclusion of unlabeled PrPc in the icv injection increased retention of
radioactively labeled PrPc by brain, demonstrating a saturable component to the brain-to-blood
transport of PrPc.
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Table 1
TCA precipitation of radioactivity in brain or serum.
5 min 20 min 30 min 60 min
Serum (% of control) 113 ± 2.2 108 ± 0.41 102 ± 1.1 103 ± 0.30
Brain (% of control) 111 ± 1.6 93 ± 3.9 68 ± 6.0 72 ± 4.4
Results are expressed as the percent of processing control radioactivity that precipitates with acidified brine. Means ± SE (n = 2).
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Table 3
Inhibition of I-PrPc uptake by 10 μg/mouse unlabeled PrPc.
CNS region I-PrPc only +PrPc
Whole brain 31.2 ± 2.0 22.3 ± 0.8**
Olfactory bulb 49.5 ± 1.2 34.8 ± 3.6**
Frontal cortex 18.4 ± 2.0 16.1 ± 2.0
Parietal cortex 22.2 ± 1.8 17.7 ± 1.4
Occipital cortex 49.3 ± 9.1 26.8 ± 4.3*
Hypothalamus 97.4 ± 6.6 105 ± 13.1
Thalamus 65.5 ± 10.2 32.8 ± 5.8*
Striatum 74.8 ± 14.9 32.9 ± 8.2*
Hippocampus 30.2 ± 1.8 29.4 ± 2.6
Cerebellum 25.6 ± 2.3 20.2 ± 1.2
Midbrain 34.1 ± 2.9 22.8 ± 1.7**
Pons medulla 24.2 ± 0.8 21.8 ± 1.5
Cervical spinal cord 65.6 ± 3.0 47.5 ± 4.6*
Thoracic spinal cord 24.6 ± 2.6 23.5 ± 2.1
Lumbar spinal cord 295 ± 62 73.5 ± 20.3*
Means are shown with their SE (n = 4–6/group). Tissue/serum ratios expressed in ml/g.
*
p <0.05 and
**
p <0.01 when compared to I-PrPc. Only for the respective region.
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